BIRMINGHAM, Ala., Oct. 20 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) and partner Shionogi & Co., Ltd. (Shionogi) today announced that positive Phase 2 data on peramivir, a potent neuraminidase inhibitor for the treatment of influenza, has been accepted as a late-breaker poster at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th annual meeting taking place from October 25 to October 28 in Washington, D.C. The study was conducted by BioCryst's development partner, Shionogi.
The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Peramivir is an antiviral agent that inhibits the interactions of
influenza neuraminidase, an enzyme which is critical to the spread of
influenza within a host. In laboratory tests, peramivir has shown activity
against viral strains that are resistant to currently available treatments
and has been safely administered to healthy subjects at high dose levels.
Peramivir is currently being studied in hospitalized and outpatient flu,
utilizing either an intramuscular or intravenous formulation. BioCryst is
currently conducting two Phase 2 studies with peramivir, a study in
subjects with acute, uncomplicated influenza, and a study in subjects with
|SOURCE BioCryst Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved